Next Article in Journal
Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events
Next Article in Special Issue
Pleiotropic Roles of Non-Coding RNAs in TGF-β-Mediated Epithelial-Mesenchymal Transition and Their Functions in Tumor Progression
Previous Article in Journal
Exosomal MicroRNAs in Breast Cancer towards Diagnostic and Therapeutic Applications
Previous Article in Special Issue
Phenotypic Plasticity and Cell Fate Decisions in Cancer: Insights from Dynamical Systems Theory
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessFeature PaperReview
Cancers 2017, 9(7), 72; doi:10.3390/cancers9070072

Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer

Laboratoire Ecologie et Biologie des Interactions, Equipe SEVE, Université de Poitiers, UMR CNRS 7267, F-86073 Poitiers, France
Division of Hematology-Oncology, Medical University of South Carolina, 39 Sabin St., MSC 635, Charleston, SC 29425, USA
Author to whom correspondence should be addressed.
Academic Editor: Samuel C. Mok
Received: 29 May 2017 / Revised: 17 June 2017 / Accepted: 17 June 2017 / Published: 24 June 2017
(This article belongs to the Special Issue The Epithelial-to-Mesenchymal Transition (EMT) in Cancer)
View Full-Text   |   Download PDF [981 KB, uploaded 6 July 2017]   |  


Lung cancer is the leading cause of cancer deaths worldwide. It is an aggressive and devastating cancer because of metastasis triggered by enhanced migration and invasion, and resistance to cytotoxic chemotherapy. The epithelial to mesenchymal transition (EMT) is a fundamental developmental process that is reactivated in wound healing and a variety of diseases including cancer where it promotes migration/invasion and metastasis, resistance to treatment, and generation and maintenance of cancer stem cells. The induction of EMT is associated with reprogramming of the epigenome. This review focuses on major mechanisms of epigenetic regulation mainly in lung cancer with recent data on EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit ), the catalytic subunit of the PRC2 (Polycomb Group PcG), that behaves as an oncogene in lung cancer associated with gene repression, non-coding RNAs and the epitranscriptome. View Full-Text
Keywords: chromatin modifications; EMT; Epigenetics; Epitranscriptomics; EZH2; non-coding RNAs; NSCLC; SCLC chromatin modifications; EMT; Epigenetics; Epitranscriptomics; EZH2; non-coding RNAs; NSCLC; SCLC

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Roche, J.; Gemmill, R.M.; Drabkin, H.A. Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer. Cancers 2017, 9, 72.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top